RECURRENT FALLOPIAN TUBE CARCINOMA

This study tests whether combining two drugs, cediranib and olaparib, works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum-based chemo. About 582 women will be randomly assign…

This early-phase trial tests whether adding an experimental drug called berzosertib to standard chemotherapy (carboplatin and gemcitabine) can better treat ovarian, peritoneal, or fallopian tube cancer that has returned and spread. The study involves 35 adults with platinum-sensi…

This study tests whether adding immunotherapy (atezolizumab) and/or a blood vessel blocker (bevacizumab) to standard chemo (pegylated liposomal doxorubicin) works better for ovarian cancer that has stopped responding to platinum drugs. About 444 women with recurrent ovarian, fall…

This early-phase trial tests a new targeted drug called MLN0128 combined with bevacizumab (Avastin) in about 50 patients whose glioblastoma or other solid tumors have returned or not responded to standard treatment. The main goal is to find the safest dose and see how the body ha…

This phase II trial tests whether adding the immunotherapy tremelimumab to the PARP inhibitor olaparib works better than olaparib alone for women with platinum-sensitive recurrent ovarian, fallopian tube, or peritoneal cancer. About 61 participants will receive either olaparib al…

This phase 2 trial tests whether adding an experimental drug called M6620 (berzosertib) to standard gemcitabine chemotherapy helps women with ovarian, fallopian tube, or primary peritoneal cancer that came back after platinum-based treatment. About 70 participants will receive ei…

This early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …

This study tests whether olaparib (a targeted drug) alone or combined with cediranib (which blocks tumor blood vessels) works better than standard platinum chemo for women whose ovarian, fallopian tube, or peritoneal cancer has returned after initial treatment. About 579 particip…

This phase 3 trial tests two different chemotherapy regimens, with or without the targeted drug bevacizumab, as first treatment for a rare type of ovarian or fallopian tube cancer called mucinous epithelial cancer. About 50 patients with newly diagnosed or recurrent cancer will b…

This early-phase trial tests a new drug called peposertib combined with a standard chemotherapy (PLD) in people with ovarian or related cancers that have stopped responding to platinum-based treatment. The main goal is to find the safest dose and understand side effects. About 54…

This early-phase trial tests the safety and best dose of two drugs, APG-1252 and cobimetinib, given together to people whose ovarian or endometrial cancer has come back. The drugs work by blocking proteins that help cancer cells survive and grow. The goal is to see if the combina…

This study tests a drug called mirvetuximab soravtansine in people with a specific type of recurrent ovarian cancer that has high levels of a protein called folate receptor alpha. The drug delivers chemotherapy directly to cancer cells to try to slow or stop the cancer from growi…

This study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …

This study tests whether adding an experimental drug (AZD1775) to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 women will be randomly assigned to receive eith…

This early-phase trial tests a new approach for people with ovarian, fallopian tube, or peritoneal cancer that has returned or not responded to standard treatments. Patients receive their own T cells, which are genetically modified to recognize and attack cancer cells, along with…

This trial tests a new drug combination for women with recurrent ovarian cancer that has come back after initial treatment. The study includes 54 participants and uses an antibody called oregovomab along with standard chemotherapy and bevacizumab. The goal is to see if this mix i…

This early-phase trial tests whether giving heated chemotherapy directly into the abdomen during surgery can help prevent cancer from coming back in people with advanced ovarian, fallopian tube, uterine, or peritoneal cancer. About 40 participants will receive the heated chemo du…

This study tests a drug called adavosertib, given alone or with olaparib, in women with ovarian, fallopian tube, or peritoneal cancer that has returned and stopped responding to PARP inhibitors. The goal is to see if these drugs can shrink tumors or stop them from growing. About …

This study tests a new combination of three FDA-approved drugs (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the triple therapy shrinks tumors…

This study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…

This early-phase trial tests a new approach for recurrent ovarian, fallopian tube, or peritoneal cancer. Doctors take stem cells from the patient's fat tissue, infect them with a modified measles virus, and inject them into the abdomen. The idea is that the stem cells will delive…